- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026
The Weight Loss 4 ME Program is tailored to work with your specific needs, goals, and lifestyle
Amps up the fat-burning process and decreases overall body fat %
Through expert medical supervision, customized nutritional plans, and targeted exercise guidance, we help you achieve sustainable and lasting weight loss results
Weekly weigh-ins under consistent conditions provide meaningful data
game, enjoying a boogie at a disco night, or on a bike ride along the Thames